Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer.
BACKGROUND
Urothelial bladder cancer is the ninth most common cancer. Despite surgical and chemotherapeutic treatment the prognosis is still poor once bladder cancer progresses to a muscle-invasive state. Discovery of new diagnostic markers and pathophysiologic effectors might help to contribute to novel diagnostic and therapeutic options. The extracellular matrix microenvironment shaped by the extracellular matrix critically affects tumor cell and stroma cell functions. Therefore, aim of the present study was to assess the possible implication of the small leucine-rich proteoglycan biglycan in progression of human urothelial bladder cancer.


RESULTS
For this purpose tumor biopsies of 76 bladder cancer patients with different tumor stages (pTa, pT1-T4) were investigated with respect to biglycan expression and correlated with a long-term (10 years) clinical follow-up. Interestingly, higher biglycan mRNA expression was associated with higher tumor stages and muscle invasiveness. In vitro knock-down of endogenous biglycan in human urothelial carcinoma cells (J82 cells) increased proliferation, whereas addition of recombinant biglycan and overexpression of biglycan inhibited tumor cell proliferation. In line with this growth-inhibitory effect of biglycan, transplantation of J82 cells after knock-down of biglycan resulted in significantly increased growth of subcutaneous xenograft tumors in nude mice in vivo. Furthermore, treatment with two anti-proliferative, multi-receptor tyrosine kinase inhibitors-sunitinib and sorafenib-strongly upregulated biglycan expression. Collectively, the experimental data suggest that high biglycan expression is associated with reduced tumor cell proliferation. In accordance, Kaplan-Meier analysis revealed higher 10-year survival in patients with high biglycan mRNA expression in tumor biopsies.


CONCLUSIONS
In conclusion, the present data suggest that biglycan is an endogenous inhibitor of bladder cancer cell proliferation that is upregulated in response to anti-proliferative tyrosine kinase inhibitors. In addition, high biglycan expression is associated with favorable prognosis.
Department of Urology, Essen Medical School, University Duisburg-Essen, Essen, Germany.
Christian
C
Niedworok
Katharina
K
Röck
Inga
I
Kretschmer
Till
T
Freudenberger
Nadine
N
Nagy
Tibor
T
Szarvas
Frank
F
Vom Dorp
Henning
H
Reis
Herbert
H
Rübben
Jens W
JW
Fischer
D000818:Animals; D058578:Biglycan / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007930:Leucine / Q000737:chemistry*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012333:RNA, Messenger / Q000235:genetics; D000077157:Sorafenib; D000077210:Sunitinib; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*
D058578:Biglycan; D007211:Indoles; D010671:Phenylurea Compounds; D011758:Pyrroles; D012333:RNA, Messenger; D009536:Niacinamide; D000077157:Sorafenib; D007930:Leucine; D000077210:Sunitinib